Hormone combo may cut breast cancer risk in women with hot flashes

NCT ID NCT04821141

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This study tests whether a combination of bazedoxifene and conjugated estrogens can lower breast cancer risk in women going through menopause who have hot flashes. About 120 women at higher risk for breast cancer will take the drug for 6 months or be placed on a waiting list. Researchers will measure changes in breast density and cell growth to see if the treatment reduces risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Northwestern Medical Center

    Chicago, Illinois, 60601, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • University of California San Francisco

    San Francisco, California, 94115, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

Conditions

Explore the condition pages connected to this study.